NRx Pharmaceuticals’ (NRXP) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright currently has a $19.00 price target on the stock. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($1.75) EPS and FY2025 earnings at ($0.08) EPS.

Several other equities analysts have also recently issued reports on NRXP. EF Hutton Acquisition Co. I raised NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a report on Thursday, September 12th.

NRx Pharmaceuticals Trading Up 1.6 %

NRXP opened at $1.29 on Monday. The company has a market cap of $15.60 million, a P/E ratio of -0.61 and a beta of 1.27. NRx Pharmaceuticals has a 12 month low of $1.10 and a 12 month high of $7.33. The business’s 50-day moving average price is $1.38 and its 200-day moving average price is $2.14.

Institutional Trading of NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC acquired a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.